LumiraDx Ltd

LumiraDX Ltd. is a next-generation point of care diagnostics company, which engages in the provision of an innovative diagnostic platform that supports a menu of tests with lab-comparable performance at the point of care. The firm's diagnostic testing solutions are being deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. It also has a comprehensive portfolio of COVID-19 testing solutions from the lab to point of need. The company was founded by Ronald Zwanziger, David Scott, and Jerry McAleer in 2014 and is headquartered in London, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LumiraDX Ltd. is a point of care diagnostics company, which engages in the provision of a diagnostic platform that supports tests with lab-comparable performance at the point of care. The company was founded by Ronald Zwanziger, David Scott, and Jerry McAleer in 2014 and is headquartered in Waltham, MA.

LumiraDx Limited's (LMDX) CEO Ron Zwanziger On Q3 2021 Results - Earnings Call Transcript

LONDON, Nov. 10, 2021 /PRNewswire/ -- LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021. Revenue of $109.1M for the three months ended Sept.

LumiraDx Reports Third Quarter 2021 Financial Results

LONDON, Nov. 2, 2021 /PRNewswire/ -- LumiraDx  (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, November 10, 2021. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to review the financial results and business highlights.

LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10

LONDON, Nov. 1, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX) a next-generation point of care (POC) diagnostics company announced that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authorized SARS-CoV-2 Antigen Test has been expanded to include screening of asymptomatic individuals. This claim builds on its existing claim that covers use of the test in individuals suspected of COVID-19 by their healthcare provider within 12 days of symptom onset.

LumiraDx Announces the Intended Use for its FDA EUA Authorized High Sensitivity COVID-19 Antigen Test has been Expanded to Include Testing of Asymptomatic Individuals

LumiraDx (NASDAQ:LMDX) has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test.  The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.

Why Are LumiraDx Shares Trading Higher Today?

LumiraDx (NASDAQ: LMDX) has received emergency user approval for the SARS-CoV-2 Antigen test in India from the Central Drugs Standard Organisation. The diagnostic Antigen test is designed to detect antigen nucleocapsid protein from nasal swab, and results are available within 12 minutes of the sample application.

Here is how LumiraDx is making COVID-19 testing easier

The stock price of LumiraDx (NASDAQ: LMDX) increased by over 30% pre-market today. This is why it happened.

LMDX Stock: Why It Substantially Increased Today

LONDON, Oct. 20, 2021 /PRNewswire/ -- Today, LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics testing company announced it has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test for use in India. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.

LumiraDx receives approval for its COVID-19 Antigen Test for use in India

LONDON, Oct. 15, 2021 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostic company, today announced it has submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). The microfluidic immunofluorescence assay can quickly verify infection for patients suspected of flu and/or COVID-19 to aid diagnosis and clinical decision making.

LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test

News for LumiraDx Ltd Stock (LMDX)